Rubicon Facebook Rubicon Linkedin

Rubicon Research enters into strategic marketing partnership with Wellesta Holdings

Thane, Mumbai (India), June 25, 2021

Today, Rubicon Research Private Limited, a leading specialty pharmaceutical company, announced it has entered into a licensing and supply partnership with Wellesta Holdings to expand its global presence in the Asia Pacific region.

The marketing partnership supports the company’s global business development efforts and focusses on their proprietary and market leading range of Nicotine Lozenges (2 mg and 4 mg). It aims to transform lives in the Asia Pacific region by providing access to a superior Nicotine Replacement Therapy product. Rubicon Research is among the top two manufacturers of private label nicotine lozenges in the US—over 50 million units were sold in 2020. Rubicon Consumer Healthcare Pvt Ltd (a subsidiary of Rubicon Research) also markets these products in India through their BounceTM range of Nicotine Lozenges. Extensive taste evaluation studies have been done in the US to develop three refreshing flavors —cherry, cinnamon, and mint.

“We are excited to partner with Wellesta Holdings for the promotion and distribution of our products in the Asia Pacific region. Finding the right partner who is aligned with our vision and core values is important for us. Through this partnership we can leverage Wellesta’s powerful sales, marketing, and distribution networks to provide an innovative product that helps people take charge of their health,” said Parag Sancheti, Chief Executive Officer, Rubicon Research.

While talking about this unique product, Milan Paleja, Chairman and Managing Director of Wellesta, said, “With this collaboration we aim to help smokers quit the habit of smoking and live healthier lives. We will launch this smoking cessation product in Singapore, Indonesia, Malaysia, Philippines and Thailand and it will be sold under a Wellesta brand.”

About Bounce™ Nicotine Lozenges
Bounce™ Nicotine Lozenges work on the principle of Nicotine Replacement Therapy and are a great quit smoking aid as they are proven to relieve nicotine cravings and alleviate withdrawal symptoms. The US FDA approved, sugar-free lozenges are a smart and healthy way to manage a smoking habit. To know more please visit .

About Rubicon Research
Rubicon Research is an IP led, specialty pharmaceutical company that develops, manufactures and commercializes its value-added formulations for the global market. The company leverages its proprietary technologies and specialized formulation development skills to provide solutions to complex delivery challenges, enabling better patient outcomes. The company operates out of 4 locations across India, USA and Canada.

Rubicon Research holds more than 50 issued patents in drug delivery technologies and its portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, ophthalmic, injectable, sterile, topical, drug device combinations, and fixed-dose combinations. Its flagship manufacturing facility at Ambernath has been inspected by leading global health authorities, including the US FDA and UK MHRA.

Rubicon Research is a portfolio company of General Atlantic, a global growth equity investor with nearly USD 35 billion in assets under management.

For additional information, please visit or LinkedIn, Facebook, Twitter.

About Wellesta Holdings
Wellesta Holdings Pte Ltd is a healthcare company headquartered in Singapore with a direct market presence in South-east Asia & India and partnering in MENA. We aim to serve clients and consumers through commercial and marketing support using an innovative approach across the Wellesta value chain. We work with companies to expand their presence in SEA & India as strategic partner for companies present in these markets and acts as a representative for companies that are not present in these markets and would like to sell/market their products in the region.

Wellesta Holdings operates in a spectrum of business verticals under our Partner Brands and Own Brands, including Pharmaceutical, Nutraceuticals, OTC and Medical devices. Being led by industry-proven leaders, Wellesta aims to be an extended arm for principals through win-win partnership and provide superior quality products and services at right price, by working at full compliance and transparency in business approach.

For additional information, please visit our website or LinkedIn.

For queries, please contact:

Kermin Bhot
Email at: